| Summary: | Obesity is one of the prevalent chronic diseases in human and companion animals usually associated with several metabolic disorders. The gut commensal bacterium <i>Akkermansia muciniphila</i> (<i>A. muciniphila</i>) is known for its therapeutic effects on metabolic disorders and inflammations. Here, we isolated the <i>A. muciniphila</i> AKK2 strain from the feces of interferon-inducible protein 204<sup>−/−</sup> (IFI204<sup>−/−</sup>) mice and further evaluated its anti-obesity effects on high-fat diet (HFD)-fed C57BL/6J mice and beagles. The results showed that it effectively controlled weight gain. Microbiome analysis using 16S rRNA gene sequencing revealed that HFD alters gut microbiota composition and <i>A. muciniphila</i> AKK2 increases the <i>Firmicutes/Bacteroidetes</i> (F/B) ratio in beagles. Furthermore, we prepared microcapsules containing <i>A. muciniphila</i> AKK2, and tolerance tests showed the encapsulation maintained high viability and stability in an aerobic environment and simulated the secretion of gastrointestinal fluids. Overall, this study widens the spectrum of <i>A. muciniphila</i> applications to prevent obesity.
|
|---|